What is the potential benefit of using allosteric modulators over traditional agonist or antagonist approaches?

Allosteric modulators can offer more targeted and effective treatments by modifying the receptor's activity without directly activating it, potentially reducing side effects.

Are there any existing clinical trials or studies that have investigated these compounds in humans?

The patent application does not mention specific clinical trial data, but it is likely that further research will be conducted to evaluate the safety and efficacy of these compounds in human subjects.

When can we expect these allosteric modulators to become available for therapeutic use?

The timeline for commercial availability is uncertain, as it depends on various factors including further research, regulatory approvals, and market demand.

What are the potential therapeutic applications of cannabinoid acid ester compounds?

The patent suggests that these compounds could be used for a range of medical conditions, including pain management, inflammation, and neurological disorders. However, further research is needed to confirm their efficacy.

Are there any clinical trials planned or underway to test the safety and efficacy of cannabinoid acid ester compositions?

The patent application does not mention specific clinical trials, but it may be assumed that Epm Group Inc. will conduct research to support the development of these novel compositions.

When can we expect to see cannabinoid acid ester-based products on the market?

It is difficult to predict a specific timeline for market availability, as the patent process and product development timelines are often lengthy and subject to various factors.

close up photo of woman having a neck pain

Cannabis News

Cannabis Patent & Innovation Watch: October 05, 2026

By CEDclinic_admin

2 Min Read

Comments Off

EVIDENCE & IP RADAR

Cannabis Patent & Innovation Watch: October 05, 2026

A structured analysis of 2 newly published cannabis, cannabinoid, and drug delivery patents evaluating formulation novelty, therapeutic claims, and clinical relevance.

PATENT #1 • US20260115176A1 2026-04-30

Stanford Researchers Unveil Allosteric Modulators for Neuropathic Pain Relief

Assignee: Leland Stanford Junior University | Inventors: Sanjay Malhotra, Brian K. Kobilka, Kaavya Krishna Kumar, Angel Resendez

The invention describes methods for treating neuropathic pain using compounds with a phenyl-indole scaffold that modulate the cannabinoid type 1 receptor (CB1R). Pharmaceutical compositions containing these compounds and pharmaceutically acceptable carriers are also provided. The claimed invention focuses on allosteric modulation, which is distinct from traditional agonist or antagonist approaches.

Clinical Significance: This patent’s focus on CB1R allosteric modulators could lead to more targeted and effective treatments for neuropathic pain, potentially reducing the need for high-dose opioids or other conventional analgesics. The clinical impact of this innovation is significant, as it addresses a major unmet need in chronic pain management.

View Primary Patent Disclosure (US20260115176A1) →

PATENT #2 • US20260069618A1 2026-03-12

“Epm Group Inc. Files Patent on Cannabinoid Acid Ester Compositions”

Assignee: Epm Group Inc | Inventors: Reshef Swisa, Salomon Sacal, Ron Shahrabani

The claimed invention involves pharmaceutical compositions containing cannabinoid acid ester compounds, including THCA, CBGA, and CBNA esters, which can be used alone or in combination with other cannabinoids for various therapeutic applications. These compositions may offer improved bioavailability and efficacy compared to existing cannabis products.

Clinical Significance: This patent’s focus on cannabinoid acid ester compounds could lead to the development of targeted therapies for specific medical conditions, such as pain management, inflammation, or neurological disorders. However, further research is needed to confirm the safety and efficacy of these novel compositions. The potential for improved bioavailability may also enhance the therapeutic effects of cannabinoids.

View Primary Patent Disclosure (US20260069618A1) →

Physician-Led, Whole-Person Care

A doctor who takes the time to truly understand you.

Personal care that starts with listening and is guided by experience and ingenuity.

Leave a Message Metabolic Care Cannabis Consultation

Get the next evidence review in your inbox

Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.

Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.

Site index

Cannabis Patent & Innovation Watch: October 05, 2026

Cannabis Patent & Innovation Watch: October 05, 2026

Stanford Researchers Unveil Allosteric Modulators for Neuropathic Pain Relief

“Epm Group Inc. Files Patent on Cannabinoid Acid Ester Compositions”

Read next

Related

Tags:

CEDclinic_admin

Other Articles

Patent Watch: Lonza Pairs Cannabinoids With Musculoskeletal Nutrition

Cannabis Crispy Brussels Sprout Leaves Recipe

Site index

Location & Contact

Get the free cannabinoid temperature chart